Roivant, Priovant Launch Newly Approved Rare Disease Drug Lisraya at $35,000 a Month
What's Happening
Roivant and its partner Priovant Therapeutics have launched Lisraya (brepocitinib) in the U.S. at a list price of $35,000 for a 30-day supply.
The drug was approved by the FDA on August 27 for dermatomyositis, a rare autoimmune disease that causes painful skin rashes and progressive muscle weakness. Lisraya is the first targeted oral treatment for the condition. (reuters.com)
Our Article: Reuters article
The Drug Is Already Available
Unlike many newly approved medicines that take weeks or months to reach pharmacies, Lisraya launched immediately after FDA approval.
Priovant CEO Ben Zimmer told Reuters that prescribing is already open and that the company had received its first patient prescriptions by August 28. (reuters.com)
The companies are also offering a patient-support program that can reduce eligible patients' out-of-pocket costs to $0. (reuters.com)
What Is Dermatomyositis?
Dermatomyositis is a rare autoimmune disease affecting the skin and muscles.
It can cause:
- Painful skin rashes.
- Progressive muscle weakness.
- Difficulty with physical activity.
- Reduced physical functioning.
- Significant deterioration in quality of life.
The condition affects fewer than 5,000 people in the United States, according to the National Institutes of Health. (reuters.com)
How Lisraya Works
Lisraya is brepocitinib, a targeted immune-system therapy designed to inhibit TYK2 and JAK1 pathways involved in inflammation.
The goal is to address the underlying immune activity driving dermatomyositis rather than relying primarily on broad immunosuppression.
This is particularly significant because long-term use of steroids, which have traditionally played an important role in treatment, can cause substantial side effects. (reuters.com)
Clinical Results
In the late-stage clinical trial, patients receiving 30 mg of Lisraya daily achieved a mean total improvement score of 46.5 after 52 weeks, compared with 31.2 for patients receiving placebo.
The companies said statistically significant benefits appeared as early as four weeks into treatment. (reuters.com)
The treatment improved both the skin and muscle manifestations of the disease and helped reduce or eliminate the need for steroids in some patients. (reuters.com)
What the $35,000 Price Means
The $35,000 figure is the list price for a 30-day supply, not necessarily what every patient or insurer will pay.
The companies are offering financial assistance for eligible patients, potentially reducing out-of-pocket costs to zero. (reuters.com)
Roivant CEO Matt Gline estimated that the net annual value to the company per patient could be in the low-to-mid $300,000 range for patients receiving a full year of therapy.
However, he cautioned that adoption is expected to build gradually. (reuters.com)
Commercial Opportunity
Despite the very small patient population, the companies see substantial commercial potential.
Roivant and Priovant expect Lisraya to have U.S. market exclusivity until at least 2039. (reuters.com)
The drug's high price reflects the economics often associated with rare-disease medicines, where manufacturers have a relatively small eligible population over which to spread development and commercialization costs.
Who Owns the Drug?
The development structure is itself notable.
Pfizer licensed brepocitinib to Priovant in 2021.
Priovant is a joint company created by Pfizer and Roivant. Roivant owns 71%, while Pfizer holds a 24% stake. (reuters.com)
This gives Roivant the leading ownership position while Pfizer remains a significant partner.
Why This Matters to Rare-Disease Care
Lisraya represents a major change in treatment for dermatomyositis because patients now have a targeted oral therapy rather than relying primarily on steroids and other broad immunosuppressive treatments.
It also illustrates how rare-disease companies can build significant commercial opportunities around very small patient populations when a therapy addresses a serious condition with limited alternatives.
Impact on Healthcare
- Patients: The availability of an oral targeted treatment could provide a more convenient alternative to existing treatment approaches.
- Physicians: Dermatologists, rheumatologists and other specialists treating dermatomyositis now have a new targeted treatment option.
- Specialty Pharmacy: The drug's high price and rare-disease status make specialty-pharmacy distribution, reimbursement support and patient assistance particularly important.
- Rare-Disease Industry: The launch demonstrates the continued commercial potential of developing targeted therapies for very small patient populations.
Looking Ahead
The companies expect adoption to build gradually, despite the drug already being commercially available. (reuters.com)
The size of the eligible population, physician awareness, diagnosis rates, insurance coverage and patient access will all influence how quickly Lisraya gains market share.
The companies also have the potential to expand the use of brepocitinib beyond dermatomyositis if additional indications are successfully developed.
Why This Matters
This is a significant U.S. healthcare industry story because it covers the immediate commercial launch of a newly FDA-approved rare-disease therapy, its pricing, patient access strategy and the economics of specialty pharmaceuticals.
It also shows how rare-disease treatments can command high prices while requiring extensive patient-support and reimbursement infrastructure to reach eligible patients.
Key Takeaways
- Roivant and Priovant launched Lisraya immediately after FDA approval. (reuters.com)
- The list price is $35,000 per 30-day supply.
- Lisraya is the first targeted oral treatment for dermatomyositis.
- Dermatomyositis affects fewer than 5,000 people in the U.S.
- The companies have already received their first patient prescriptions.
- Eligible patients can potentially reduce their out-of-pocket cost to $0 through the patient-support program.
- Clinical trial patients receiving 30 mg daily had a mean improvement score of 46.5 vs. 31.2 for placebo after 52 weeks.
- Roivant expects U.S. market exclusivity through at least 2039. (reuters.com)
What This Means for Healthcare Marketers
The launch is highly relevant to rare disease, specialty pharmaceuticals, dermatology, rheumatology, specialty pharmacy, patient access and provider targeting. With fewer than 5,000 potential U.S. patients, commercial success will depend heavily on accurately identifying the relatively small network of specialists, treatment centers and eligible patients involved in dermatomyositis care.